Discovery of 2-methylpyridine-based biaryl amides as γ-secretase modulators for the treatment of Alzheimer's disease.
Bioorg Med Chem Lett
; 23(23): 6447-54, 2013 Dec 01.
Article
em En
| MEDLINE
| ID: mdl-24139583
ABSTRACT
γ-Secretase modulators (GSMs) are potentially disease-modifying treatments for Alzheimer's disease. They selectively lower pathogenic Aß42 levels by shifting the enzyme cleavage sites without inhibiting γ-secretase activity, possibly avoiding known adverse effects observed with complete inhibition of the enzyme complex. A cell-based HTS effort identified the sulfonamide 1 as a GSM lead. Lead optimization studies identified compound 25 with improved cell potency, PKDM properties, and it lowered Aß42 levels in the cerebrospinal fluid (CSF) of Sprague-Dawley rats following oral administration. Further optimization of 25 to improve cellular potency is described.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Picolinas
/
Secretases da Proteína Precursora do Amiloide
/
Doença de Alzheimer
/
Amidas
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article